ShareValue scores for RAFA.TA: Valuation 50, Quality 59, Growth 50, Health 53.

RAFA.TA
TASE

Rafa Laboratories Ltd.

₪16.40(-0.06%)

Updated

Loading chart...
Sentiment

Pulse

Rating

Moderate

Trap Risk

P/E to median

Not enough data
Valuation
50
Fair Value

vs Tel Aviv-listed Healthcare stocks

Price vs Value
Quality
59
Moderate
Business Strength
Growth
50
Moderate
Revenue & Earnings
Health
53
Moderate
Financial Stability
Price trend
81
Strong
Separate from the four scores

Company Details

About

Rafa Laboratories Ltd., a pharmaceutical company, manufactures, markets, and distributes prescription (Rx) and over-the-counter (OTC) medicines in Israel. The company offers sterile and aseptic injectable products, as well as formulations for combination devices such as auto-injectors. It also offers primary and secondary packaging solutions, including blisters, bottles, tubes, ampoules, cartridges, suppositories, and serialization services. In addition, it develops and offers auto-injector products for emergency use and protection against chemical warfare, as well as products to treat trauma, pain, and additional ABC (atomic, biological, and chemical) threats. The company was founded in 1937 and is based in Jerusalem, Israel.

Score Analysis

AI Investment Thesis

Powered by DeepSeek. For research only. Not financial advice.

Sources:[1][2][3]

Rafa Laboratories Ltd. is fairly valued: its P/S of 3.60 is higher than 50% of Tel Aviv-listed Healthcare peers, while P/E and EV/EBITDA are not available.

Data as of:Nov 20, 2026

By using ShareValue.ai you agree to our Terms and Privacy Policy. Educational platform, not investment advice.